NCT05859048 Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure
| NCT ID | NCT05859048 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardiology Research UBC |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,360 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,360 participants in total. It began in 2024-03-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure. The main question\[s\] it aims to answer are: • will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care? Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm: SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure. Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months
Eligibility Criteria
Inclusion Criteria: * Male or female \> 40 years of age * Informed consent * At least two additional risk factors for Heart Failure (HF): * Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or \>70% left anterior descending, circumflex or right coronary artery)). * Diabetes type 1 or 2. * Persistent or permanent atrial fibrillation. * Previous ischemic or embolic stroke. * Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis \>50% of major peripheral arterial vessel. * Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)\<60 milliliters per minute (mL/min)/1.73m2 or eGFR 60-90 mL/min/1.73m2 and urine albumin-creatinine ration (UACR) \>300mg/g). * Regular loop diuretic use for \>30 days within 12 months prior to consent. * Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or treatment with national guidance advocated COPD therapy. Exclusion Criteria: * Inability to give informed consent (e.g. due to significant cognitive impairment). * Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause. * Renal replacement therapy. * Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.
Contact & Investigator
Nathaniel M Hawkins, MD
PRINCIPAL INVESTIGATOR
Associate Professor of Medicine, UBC Division of Cardiology
Frequently Asked Questions
Who can join the NCT05859048 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05859048 currently recruiting?
Yes, NCT05859048 is actively recruiting participants. Contact the research team at naomi.uchida@ubc.ca for enrollment information.
Where is the NCT05859048 trial being conducted?
This trial is being conducted at Vancouver, Canada, Montreal, Canada, Sherbrooke, Canada.
Who is sponsoring the NCT05859048 clinical trial?
NCT05859048 is sponsored by Cardiology Research UBC. The principal investigator is Nathaniel M Hawkins, MD at Associate Professor of Medicine, UBC Division of Cardiology. The trial plans to enroll 1,360 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.